局部晚期宫颈癌根治性放化疗等待时间与生存的关系
本研究基于国家癌症数据库2004至2016年数据,回顾性纳入13,617例接受根治性同步放化疗的局部晚期宫颈癌患者,分析等待时间与全因死亡的关系。中位等待时间为6周,多因素分析显示等待6.1至9.8周与等待6周相比,全因死亡风险未增加;结论提示在无侵袭性肿瘤因素时,短期等待可能不增加死亡风险。
要点
- 中位等待时间为6周(IQR 4-8周)。
- 等待6.1至9.8周与等待6周相比,全因死亡风险未增加。
- 无侵袭性肿瘤因素时,短期等待可能不增加死亡风险。
核心结论
- 在无侵袭性肿瘤因素时,短期等待开始根治性同步放化疗可能不增加局部晚期宫颈癌患者的死亡风险。
研究设计与样本
- 回顾性观察研究,查询国家癌症数据库2004至2016年数据,纳入13,617例接受根治性同步放化疗且等待时间已知的局部晚期宫颈癌患者。
主要发现
- 中位等待时间为6周(IQR 4-8周)。
- 多因素分析中,年龄较大、非西班牙裔黑人和西班牙裔、近期诊断年份、医疗补助和无保险状态、合并症及无淋巴结转移与更长等待时间相关(P<.05)。
- 侵袭性肿瘤因素(分化较差、肿瘤较大、淋巴结转移、更高癌症分期)更可能等待时间短(P<.05)。
- 控制协变量后,等待6.1至9.8周与等待6周相比,全因死亡风险未增加。
- 按组织学、癌症分期、肿瘤大小或近距离放疗使用分层后,关联相似。
关键数值与推荐
- 中位等待时间6周(IQR 4-8周)。
- 等待6.1至9.8周与等待6周相比,全因死亡风险未增加。
临床怎么用
- 在缺乏侵袭性肿瘤因素时,短期等待开始根治性同步放化疗可能不增加死亡风险,可考虑在疫情期间合理调整治疗安排。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The current coronavirus pandemic caused a significant decrease in cancer-related encounters resulting in a delay in treatment of cancer patients. The objective of this study was to examine the survival effect of delay in starting concurrent chemo-radiotherapy (CCRT) in women with locally-advanced cervical cancer. METHODS: This is a retrospective observational study querying the National Cancer Database from 2004 to 2016. Women with stage IB2-IVA squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix who received definitive CCRT with known wait-time for CCRT initiation after cancer diagnosis were eligible (N=13,617). Cox proportional hazard regression model with restricted cubic spline transformation was fitted to assess the association between CCRT wait-time and all-cause mortality in multivariable analysis. RESULTS: The median wait-time to start CCRT was 6 (IQR 4-8) weeks. In a multivariable analysis, older age, non-Hispanic black and Hispanic ethnicity, recent year of diagnosis, Medicaid and uninsured status, medical comorbidities, and absence of nodal metastasis were associated with longer CCRT wait-time (P<.05). Women with aggressive tumor factors (poorer differentiation, large tumor size, nodal metastasis, and higher cancer stage) were more likely to have a short CCRT wait-time (P<.05). After controlling for the measured covariates, CCRT wait-time of 6.1-9.8 weeks was not associated with increased risk of all-cause mortality compared to a wait-time of 6 weeks. Similar association was observed when the cohort was stratified by histology, cancer stage, tumor size, or brachytherapy use. CONCLUSION: An implication of this study for the current coronavirus pandemic is that in the absence of aggressive tumor factors, a short period of wait-time to start definitive CCRT may not be associated with increased risk of mortality in women with locally-advanced cervical cancer.
引用
- Matsuo K, Huang Y, Matsuzaki S, et al. Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic. Gynecol Oncol. 2021. PMID: 33771396. doi:10.1016/j.ygyno.2021.02.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。